<DOC>
	<DOC>NCT01055041</DOC>
	<brief_summary>The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting Î²2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe persistent bronchial asthma.</brief_summary>
	<brief_title>Controller Medications in the Management of Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Doxofylline</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>aged between 15 to 65 years of either sex had clinically diagnosed Bronchial asthma had poor asthma control defined by ACQ score (asthma control questionnaire) of 1.5 or greater FEV1 (Forced Expiratory Volume at 1 second) value of 50% or more of predicted improvement in FEV1 was greater than 15% after bronchodilator inhalation major illness of system other than respiratory major respiratory illness other than asthma taken long acting anti histaminic within a preceding week of enrollment Smokers Pregnant and lactating woman history of hypersensitivity to any of above drugs</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>